COVID In India: How many cases of COVID-19 has India logged in the last 24 hours? Is the country ready for a new coronavirus wave? Scroll down to know the top 10 developments. TheHealthSite.com
Serum Institute is already conducting a trial of its COVID-19 vaccine Covovax, a domestically produced version of Novavax s shot, in the 12-17 age group and has presented safety data for an initial.
Coronavirus News LIVE Updates: India has administered about 212 million doses, the most after China and the United States, but has given the necessary two doses to only about 3% of its 1.35 billion people.
Bharat Biotech’s Covaxin has been given the regular emergency use authorisation in public interest, putting it on a par with the approval granted to Serum Institute’s Covishield’s, V K Paul, member-health, Niti Aayog told reporters on Thursday.
Health Secretary Rajesh Bhushan added that the government has renegotiated the price of vaccines at a much lower level than before, without sharing any further details. “Earlier price was Rs 200 per dose and Rs 210 with taxes. After that, the re-negotiated price is significantly lower than this.”
Paul added: “Covaxin is now allowed for restricted use in emergency usage in public interest. The vaccine has stood the test of time in terms of great safety. Covaxin is now in regular emergency use authorisation, the same as Covishield,” Paul told reporters.